MGTX - メイラGTxホ―ルディングス （MeiraGTx Holdings plc）

LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 10.7 million ordinary shares at a price of $5.75 per share. MeiraGTx anticipates aggregate gross proceeds from the private placement will be approximately $60 million. The Company intends to use the proceeds from this private placement to continue to advance its pipeline of innovative gene therapy assets through clinical development, as well as for general corporate purposes.

https://www.investing.com/news/pro/meiragtx-holdings-plc-pt-lowered-to-22-at-rbc-capital-432SI-3031219

MeiraGTx Holdings plc (NASDAQ:MGTX)’s traded shares stood at 0.41 million during the last session, with the company’s beta value hitting 1.42. At the close of trading, the stock’s price was $6.01, to imply a decrease of -0.66% or -$0.04 in intraday trading. The MGTX share’s 52-week high remains $24.89, putting it -314.14% down since that … MeiraGTx Holdings plc (NASDAQ: MGTX) Shares Fall :-682.03% From The Trough – But Can It Keep Going? Read More »

As of Tuesday, MeiraGTx Holdings plc’s (NASDAQ:MGTX) stock closed at $6.11, down from $6.12 the previous day. While MeiraGTx Holdings plc has underperformed by -0.25%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MGTX fell by -70.61%, with highs and lows ranging from $24.89 to $5.70, […]

MeiraGTx Holdings plc (NASDAQ: MGTX ) announced positive clinical data from the ongoing Phase 1 AQUAx study of AAV2-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX), dry mouth symptoms. Clinically meaningful improvements in xerostomia symptoms were reported consistently across two validated PROs assessing xerostomia symptom severity. Meaningful … Full story available on Benzinga.com

-- Manufacturing facilities built to accelerate development and delivery of advanced medicines to patients using state-of-the-art technology at scale, with quality appropriate for commercialization -- Site reflects MeiraGTx''s unique, end-to-end approach to gene therapy manufacturing to expedite clinical development LONDON and NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX ), a vertically integrated, clinical stage gene therapy company, will today formally unveil its GMP manufacturing facility in Shannon, Ireland, with the Head of Irish Government, Micheál Martin, in attendance. The facility, online since earlier this year and stretching over 150,000 square feet, is the first commercial-scale gene therapy manufacturing site in Ireland. The facility is unique in its scale and integrated capabilities. The site contains three facilities, one built to be flexible and scalable for viral vector production for clinical and commercial supply, in addition, a facility to manufacture plasmid DNA – the critical starting material for producing gene therapy products – and thirdly, a Quality Control (QC) hub performing advanced biochemical quality control testing for MeiraGTx clinical and commercial programs.

The following slide deck was published by MeiraGTx Holdings plc in conjunction with this event.

MeiraGTx Holdings plc (NASDAQ: MGTX ) announced topline data from the Phase 1/2 study MGT009 of botaretigene sparoparvovec, gene therapy for X-linked retinitis pigmentosa (XLRP). Treatment with botaretigene sparoparvovec was found to be generally safe and well-tolerated. Significant improvements were demonstrated across retinal, visual functions, and functional vision in participants treated with botaretigene sparoparvovec compared to the randomized untreated control … Full story available on Benzinga.com

The following slide deck was published by MeiraGTx Holdings plc in conjunction with this event.

Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) saw an uptick in trading volume on Tuesday . 5,580 shares traded hands during mid-day trading, a decline of 97% from the previous sessions volume of 187,077 shares.The stock last traded at $22.23 and had previously closed at $21.23. Several research firms have issued reports on MGTX. Bank of []

The following slide deck was published by MeiraGTx Holdings plc in conjunction with this event.

Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) saw an uptick in trading volume on Tuesday . 5,580 shares traded hands during mid-day trading, a decline of 97% from the previous sessions volume of 187,077 shares.The stock last traded at $22.23 and had previously closed at $21.23. Several research firms have issued reports on MGTX. Bank of []

LONDON and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX ), a vertically integrated, clinical stage gene therapy company, will host a virtual R&D Day via webcast and conference call on Wednesday, December 15, 2021, from 10:00 a.m. to 12:00 p.m. ET highlighting the Company''s gene regulation platforms. MeiraGTx''s R&D Day webcast will feature a presentation by Alexandria Forbes, Ph.D., President and Chief Executive Officer. The event will provide a detailed overview of the Company''s gene regulation platforms including promoter engineering and MeiraGTx''s proprietary platform driven by novel synthetic riboswitches controlled by oral small molecules. The presentation will be followed by an audience question and answer session. MeiraGTx''s virtual R&D Day details are as follows: Wednesday, December 15, 2021, from Full story available on Benzinga.com

LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to provide an update on the Company’s AAV-hAQP1 Phase 1 AQUAx clinical trial for the treatment of radiation-induced xerostomia (RIX) on Tuesday, December 7, 2021, at 8:00 a.m. ET.

Vanguard Group Inc. lessened its stake in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 5.8% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 182,470 shares of the companys stock after selling 11,195 shares during the quarter. Vanguard Group Inc.s holdings in MeiraGTx were worth $2,829,000 at the end of the most recent quarter. []